Effect of HLA-B-associated Transcript 3 Polymorphisms on Lung Cancer Risk: A Meta-Analysis
Junfei Zhao, Hongyuan Wang, Weizhen Hu, Yuanhong Jin
Respiratory Department, The Sixth Affiliated Hospital of Wenzhou Medical University, People’s Hospital, Lishui, China (mainland)
Med Sci Monit 2014; 20:2461-2465
DOI: 10.12659/MSM.891141
Available online:
Published: 2014-11-28
Background:
The association between the HLA-B-associated transcript 3 polymorphisms and lung cancer risk is a subject of debate. We conducted a meta-analysis to evaluate the association between these polymorphisms and lung cancer susceptibility.
Material and Methods:
A systematic search of electronic databases (PubMed, EMBASE, Wanfang, and China National Knowledge Infrastructure) was performed. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated.
Results:
Ten case-control studies with 37 945 and 56 807 controls were included in this meta-analysis. Overall, a significant association between rs1052486 polymorphism and lung cancer susceptibility was observed (OR=1.07, 95% CI 1.01–1.12, P=0.01). In addition, a significant association was found for rs3117582 polymorphism (OR=1.29, 95% CI 1.22–1.37, P<0.01).
Conclusions:
This meta-analysis suggested that HLA-B-associated transcript 3 polymorphisms are risk factors for lung cancer.
Keywords: Genetic Predisposition to Disease, Lung Neoplasms - genetics, Molecular Chaperones - genetics, Polymorphism, Single Nucleotide - genetics, Risk Factors
